The U.S. Food and Drug Administration today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.
After a year of repeal and replace efforts in Congress, enrollees and community advocates are preparing for the 2018 health care open enrollment period. With substantially higher premiums, health plan exits, uncertainty around subsidies, shorter enrollment periods, and less money being spent on advertising, 2018 is projected to present new barriers to ensuring access to healthcare.
This activity is intended for primary care physicians, ID/HIV specialists, and public health and preventive medicine specialists.
The goal of this activity is to improve recognition among primary care providers of patients who could benefit from human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) medications.
Talking to patients about HIV risk may lead to a conversation about PrEP.
DSHS encourages Texas healthcare providers to enhance efforts to prevent, diagnose and treat HIV in the wake of 16 rapidly growing clusters of HIV infections in the state.
HealthHIV invites prescribing providers (MDs, DOs, NPs, PAs) nationwide to participate in a 20-minute online focus group to discuss HIV prevention & PrEP. Friday, August 4, 2017 12:00 PM EST Providers interested in participating can register online. PrEP, for Pre-Exposure Prophylaxis, is an important tool in the fight against HIV.
Texas Medical Association (TMA) spotlighted the physician’s role in providing Pre-exposure Prophylaxis (PrEP) and provided in depth information on access to, efficacy of and target groups for PrEP. While treatment for an STD might be conversation starter about PrEP, PrEP is not just for STD clinicians. Primary care physicians, Ob/Gyn specialists, and others may all … Continue reading PrEP for HIV in Texas
Pre-exposure prophylaxis regimens containing Selzentry were generally safe and well-tolerated compared with Truvada, the standard-of-care PrEP drug, according to the results of a phase 2 trial.
Texas Medicine provides talking points and information on offering PrEP to women at risk for contracting HIV. How do you know your patients are at risk for HIV? Ask tough questions.
The DSHS HIV/STD Prevention and Care Branch announces this Request for Application (RFA) to provide sustainable, integrated, routine, opt-out screening for HIV in healthcare settings in hospital systems emergency services and primary care in community health centers that serve under- and uninsured populations in high morbidity areas in Texas.
According to a retrospective study of data, women at risk for HIV are not participating in PrEP treatment. The researchers recommend targeted intervention plans to increase use among people most likely to benefit from it.
HIVE is sponsoring a discussion via Google+ Hangouts on Air. PrEP champions from various family planning clinics will share lessons learned & discuss the way forward for integration of PrEP into Family Planning Services.
The AIDS Education and Training Center (AETC) Southeast has announced a webinar series for October focused on Hepatitis C. To view the webinars, check their calendar. They also have an online curriculum for Medical Case Management. For more information, view their introductory video.
A webinar jointly provided by The American Congress of Obstetricians and Gynecologists (ACOG) and CDC’s Expert Panel on HIV Reproductive Health and Preconception Care.
A recent study of emergency department patients demonstrates the value of fourth generation HIV screenings. Over 22,000 people were tested for HIV using an antigen/antibody combination HIV assay test.
The Southeast AETC has announced a series of webinars focused on PrEP. Topics include delivery in various settings, monitoring and coverage and upcoming advances. To register for the webinars, or view upcoming topics, visit their website.
According to a recent study of 20 cities, more than 60% of men who have sex with men (MSM) are interested in pre-exposure prophylaxis (PrEP). Currently less than four percent participate in the therapy.
A recent study has demonstrated support for the use of a combination of ART and PrEP therapy in serodiscordant heterosexual couples in Kenya and Uganda. Heterosexual contact is the primary mode of transmission in Africa and the implementation of this approach could drastically reduce HIV.
HIV testing recommendations for women: An important step to achieving perinatal HIV elimination was presented on August 19 by the CDC and partners and has been archived for those that missed it. The session focuses on the rationale for testing women, understanding the new HIV Algorithm and how it impacts providers when ordering and interpreting tests, and some examples of missed opportunities in HIV prevention.
According to a new modeling study, HIV incidence could be reduced by one third if almost half of eligible men who have sex with men participated in PrEP. Treatment adherence is an important aspect in the model. Targeting individuals at a substantial risk for transmission is also key.